메뉴 건너뛰기




Volumn 26, Issue 3, 2010, Pages 301-305

Short communication: Evaluation of the effect of enfuvirtide in 11 HIV-1 vertically infected pediatric patients outside clinical trials

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; RITONAVIR; SAQUINAVIR; TENOFOVIR; TIPRANAVIR; VIRUS RNA;

EID: 77950233376     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0151     Document Type: Article
Times cited : (8)

References (10)
  • 1
    • 0038576281 scopus 로고    scopus 로고
    • Enfuvirtide, an HIV- 1 fusion inhibitor, for drug-resistant HIV infection in North and South America
    • Lalezari JP, Henry K, O'Hearn M, et al.: Enfuvirtide, an HIV- 1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175-2185.
    • (2003) N Engl J Med , vol.348 , pp. 2175-2185
    • Lalezari, J.P.1    Henry, K.2    O'Hearn, M.3
  • 2
    • 0037849954 scopus 로고    scopus 로고
    • Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia
    • Lazzarin A, Clotet B, Cooper D, et al.: Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003;348:2186-2195.
    • (2003) N Engl J Med , vol.348 , pp. 2186-2195
    • Lazzarin, A.1    Clotet, B.2    Cooper, D.3
  • 3
    • 77950242414 scopus 로고    scopus 로고
    • Analysis of virological failure through 24 weeks of treatment in the TORO pivotal studies
    • Battegay M, DeMasi R, Delehanty J, et al.: Analysis of virological failure through 24 weeks of treatment in the TORO pivotal studies. Antivir Ther 2003;8(Suppl. 1).
    • (2003) Antivir Ther , vol.8 , Issue.SUPPL. 1
    • Battegay, M.1    Demasi, R.2    Delehanty, J.3
  • 4
    • 33846081762 scopus 로고    scopus 로고
    • Susceptibility of HIV-1 non-B subtypes and recombinant variants to enfuvirtide
    • Holguin A, Faudon JL, Labernardiere JL, et al.: Susceptibility of HIV-1 non-B subtypes and recombinant variants to enfuvirtide. J Clin Virol 2007;38:176-180.
    • (2007) J Clin Virol , vol.38 , pp. 176-180
    • Holguin, A.1    Faudon, J.L.2    Labernardiere, J.L.3
  • 5
    • 4043094071 scopus 로고    scopus 로고
    • Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children
    • Church JA, Hughes M, Chen J, et al.: Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children. Pediatr Infect Dis J 2004;23:713-718.
    • (2004) Pediatr Infect Dis J , vol.23 , pp. 713-718
    • Church, J.A.1    Hughes, M.2    Chen, J.3
  • 6
    • 13244286223 scopus 로고    scopus 로고
    • Pharmacokinetics of enfuvirtide in pediatric human immunodeficiency virus 1-infected patients receiving combination therapy
    • Bellibas SE, Siddique Z, Dorr A, et al.: Pharmacokinetics of enfuvirtide in pediatric human immunodeficiency virus 1-infected patients receiving combination therapy. Pediatr Infect Dis J 2004;23:1137-1141.
    • (2004) Pediatr Infect Dis J , vol.23 , pp. 1137-1141
    • Bellibas, S.E.1    Siddique, Z.2    Dorr, A.3
  • 8
    • 4043162723 scopus 로고    scopus 로고
    • PENTA guidelines for the use of antiretroviral therapy
    • Sharland M, Blanche S, Castelli G, et al.: PENTA guidelines for the use of antiretroviral therapy. HIV Med 2004;5(Suppl 2):61-86.
    • (2004) HIV Med , vol.5 , Issue.SUPPL. 2 , pp. 61-86
    • Sharland, M.1    Blanche, S.2    Castelli, G.3
  • 9
    • 34548203506 scopus 로고    scopus 로고
    • Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients
    • Wiznia A, Church J, Emmanuel P, et al.: Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients. Pediatr Infect Dis J 2007;26:799-805.
    • (2007) Pediatr Infect Dis J , vol.26 , pp. 799-805
    • Wiznia, A.1    Church, J.2    Emmanuel, P.3
  • 10
    • 0034530906 scopus 로고    scopus 로고
    • Adherence to medication regimens among children with human immunodeficiency virus infection
    • Reddington C, Cohen J, Baldillo A, et al.: Adherence to medication regimens among children with human immunodeficiency virus infection. Pediatr Infect Dis J 2000;19: 1148-1153.
    • (2000) Pediatr Infect Dis J , vol.19 , pp. 1148-1153
    • Reddington, C.1    Cohen, J.2    Baldillo, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.